Breaking News, Promotions & Moves

Shift Bioscience Announces Board and Advisor Appointments

Lord David Prior joins as Chair of the Board, and Sir Tony Kouzarides joins as Scientific Advisor.

By: Rachel Klemovitch

Assistant Editor

Shift Bioscience (Shift), a biotech company using an AI-powered virtual cell to fight age-driven diseases, appointed Lord David Prior as Chair of the Board and Sir Tony Kouzarides as Scientific Advisor.  Prior and Kouzarides will provide crucial support to advance Shift’s therapeutic pipeline, helping to foster new industry partnerships and broaden awareness of the company’s long-term mission to treat disease by targeting underlying cellular aging. David Prior, Chair of the Board...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters